Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards-Reference-Cited by-同舟云学术

Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards

Published:2016-08-05 Issue:4 Volume:7 Page:261-270
ISSN:1868-310X
Container-title:Journal of Community Genetics
language:en
Short-container-title:J Community Genet

Author:

Soofi Hojjat^ORCID,van Leeuwen Evert

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Public Health, Environmental and Occupational Health,Epidemiology

Link

http://link.springer.com/content/pdf/10.1007/s12687-016-0274-4.pdf

Reference57 articles.

1. Aditya S (2012) Ivacaftor in cystic fibrosis: the first disease modifying agent. Int J Basic Clin Pharmacol 1:225–229

2. Anderson M, McCleary KK (2015) From passengers to co-pilots: patient roles expand. Sci Transl Med 7:291fs225–291fs225

3. Anderson DC et al (2002) Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharmacogenomics J 2:284–292. doi: 10.1038/sj.tpj.6500131

4. Bauchner H, Fontanarosa PB (2013) Restoring confidence in the pharmaceutical industry. JAMA 309:607–609

5. Bliss C (2015) Biomedicalization and the new science of race. In: Bell SE, Figert AE (eds) Reimagining (Bio) medicalization, pharmaceuticals and genetics: Old critiques and New engagements. Routledge, New York, p 192

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives and ethical considerations for return of genetics and genomics research results: a qualitative study of genomics researchers in Uganda;BMC Medical Ethics;2021-11-19